Why the study?
Does the mechanism of platelet P2Y12 receptor inhibition (reversible vs irreversible) determine the attributable safety profile and bleeding risk in patients with ACS or undergoing PCI?
Population
Patients with acute coronary syndromes (ACS) and patients undergoing percutaneous intervention (PCI)
Design
Review
Authors
Loading...
May inform bleeding risk assessment with P2Y12 inhibitors; leaves open whether mechanism-specific choices improve outcomes in ACS/PCI.
Does the mechanism of platelet P2Y12 receptor inhibition (reversible vs irreversible) determine the attributable safety profile and bleeding risk in patients with ACS or undergoing PCI?
This review highlights the importance of understanding how reversible versus irreversible mechanisms of P2Y12 receptor inhibition impact bleeding risk and safety profiles.
Becker et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: